Reverse the Resistance to PARP Inhibitors

被引:67
|
作者
Kim, Yevgeniy [1 ]
Kim, Aleksei [1 ]
Sharip, Ainur [1 ]
Sharip, Aigul [1 ]
Jiang, Juhong [2 ]
Yang, Qing [1 ]
Xie, Yingqiu [1 ]
机构
[1] Nazarbayev Univ, Sch Sci & Technol, Dept Biol, 53 Kabanbay Batyr Ave, Astana 010000, Kazakhstan
[2] Guangzhou Med Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Guangdong, Peoples R China
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2017年 / 13卷 / 02期
基金
中国国家自然科学基金;
关键词
PARP; PARP inhibitor; drug resistance; DNA repair; STRAND-BREAK REPAIR; SHOCK-PROTEIN; 90; HOMOLOGOUS RECOMBINATION; DNA-REPAIR; SECONDARY MUTATIONS; SYNTHETIC LETHALITY; MILD HYPERTHERMIA; TUMOR SUPPRESSION; CANCER-CELLS; BRCA1;
D O I
10.7150/ijbs.17240
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the DNA repair machineries is activated by Poly ( ADP- ribose) Polymerase ( PARP) enzyme. Particularly, this enzyme is involved in repair of damages to single- strand DNA, thus decreasing the chances of generating double- strand breaks in the genome. Therefore, the concept to block PARP enzymes by PARP inhibitor ( PARPi) was appreciated in cancer treatment. PARPi has been designed and tested for many years and became a potential supplement for the conventional chemotherapy. However, increasing evidence indicates the appearance of the resistance to this treatment. Specifically, cancer cells may acquire new mutations or events that overcome the positive effect of these drugs. This paper describes several molecular mechanisms of PARPi resistance which were reported most recently, and summarizes some strategies to reverse this type of drug resistance.
引用
收藏
页码:198 / 208
页数:11
相关论文
共 50 条
  • [41] PARP Inhibitors in Breast and Ovarian Cancer
    Wang, Samuel S. Y.
    Jie, Yeo Ee
    Cheng, Sim Wey
    Ling, Goh Liuh
    Ming, Heong Valerie Yue
    CANCERS, 2023, 15 (08)
  • [42] Update on PARP Inhibitors in Breast Cancer
    Zimmer, Alexandra S.
    Gillard, Mitchell
    Lipkowitz, Stanley
    Lee, Jung-Min
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (05)
  • [43] PARP inhibitors: Synthetic lethality in the clinic
    Lord, Christopher J.
    Ashworth, Alan
    SCIENCE, 2017, 355 (6330) : 1152 - 1158
  • [44] PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
    Keung, Man Yee T.
    Wu, Yanyuan
    Vadgama, Jaydutt V.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (04)
  • [45] Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
    Franchet, Camille
    Hoffmann, Jean-Sebastien
    Dalenc, Florence
    CANCERS, 2021, 13 (16)
  • [46] Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
    Matsuno, Yusuke
    Hyodo, Mai
    Fujimori, Haruka
    Shimizu, Atsuhiro
    Yoshioka, Ken-ichi
    CANCERS, 2018, 10 (10):
  • [47] Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors
    Yuna Suzuki
    Wu Wenwen
    Tomohiko Ohta
    Shin-ichi Hayashi
    Breast Cancer, 2022, 29 : 77 - 91
  • [48] Histone ADPribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions
    Zentout, Siham
    Imburchia, Victor
    Chapuis, Catherine
    Duma, Lena
    Schuetzenhofer, Kira
    Prokhorova, Evgeniia
    Ahel, Ivan
    Smith, Rebecca
    Huet, Sebastien
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (25)
  • [49] Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
    Forster, Martin
    Mendes, Ruheena
    Fedele, Stefano
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (34) : 5431 - 5441
  • [50] Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors
    Suzuki, Yuna
    Wu Wenwen
    Ohta, Tomohiko
    Hayashi, Shin-ichi
    BREAST CANCER, 2022, 29 (01) : 77 - 91